1997
DOI: 10.1006/bbrc.1997.7124
|View full text |Cite
|
Sign up to set email alerts
|

Regulation of Cre Recombinase Activity by Mutated Estrogen Receptor Ligand-Binding Domains

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

7
854
0
2

Year Published

2000
2000
2016
2016

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 898 publications
(863 citation statements)
references
References 29 publications
7
854
0
2
Order By: Relevance
“…(CreER T2 ), which has been shown to be between 4-and 10-fold more sensitive to 4-hydroxytamoxifen in vivo (Feil et al, 1997;Indra et al, 1999). 4-hydroxytamoxifen is a metabolite of tamoxifen that is generated in the liver and believed to be the active compound in binding the ER, although administration of either compound, at the same concentration, results in indistinguishable recombination efficiency (Kuhbandner et al, 2000).…”
Section: Figmentioning
confidence: 99%
“…(CreER T2 ), which has been shown to be between 4-and 10-fold more sensitive to 4-hydroxytamoxifen in vivo (Feil et al, 1997;Indra et al, 1999). 4-hydroxytamoxifen is a metabolite of tamoxifen that is generated in the liver and believed to be the active compound in binding the ER, although administration of either compound, at the same concentration, results in indistinguishable recombination efficiency (Kuhbandner et al, 2000).…”
Section: Figmentioning
confidence: 99%
“…We used three different HBD-Cre systems in an effort to develop astrocyte-specific, inducible gene recombination. Two of these are based on a mutated estrogen receptor, CreER T2 and MerCreMer (Feil et al, 1997;Zhang et al, 1996), and the third on a mutated progesterone receptor, CrePR2 (Kellendonk et al, 1996) (see Fig. 1b).…”
Section: The Steroid Responsive Systemsmentioning
confidence: 99%
“…Harfe et al (2004) furthered their analysis using a CreERT2 gene inserted into the Shh locus. CreErt2 encodes a fusion protein between the Cre recombinase and the activation domain of the estrogen nuclear receptor that is activated in embryos when tamoxifen is provided to the mother (Feil et al, 1997). This way, could label Shh-expressing cells at selected times during development.…”
Section: Mechanism Of Action Of Shh: Cellular Aspectsmentioning
confidence: 99%